Outlook Therapeutics Inc. (OTLK)
NASDAQ: OTLK
· Real-Time Price · USD
0.97
-0.02 (-1.87%)
At close: Sep 25, 2025, 3:59 PM
0.96
-1.41%
After-hours: Sep 25, 2025, 05:16 PM EDT
-1.87% (1D)
| Bid | 0.92 |
| Market Cap | 43.26M |
| Revenue (ttm) | 1.68M |
| Net Income (ttm) | -43.44M |
| EPS (ttm) | -0.84 |
| PE Ratio (ttm) | -1.16 |
| Forward PE | -1 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 0.99 |
| Volume | 1,533,593 |
| Avg. Volume (20D) | 3,379,809 |
| Open | 0.96 |
| Previous Close | 0.99 |
| Day's Range | 0.93 - 0.99 |
| 52-Week Range | 0.79 - 6.98 |
| Beta | 0.49 |
| Ex-Dividend Date | n/a |
About OTLK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol OTLK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for OTLK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsOutlook Therapeutics Inc. is scheduled to release its earnings on
Dec 26, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-21.91%
Outlook Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
3 weeks ago
-54.2%
Outlook Therapeutics shares are trading lower after the FDA issued a Complete Response Letter for its resubmitted ONS-5010 BLA.
1 month ago · seekingalpha.com
Outlook Therapeutics: Why The Odds Point To A Favorable FDA DecisionFDA approval for Lytenava might come next week, I see Outlook Therapeutics at a pivotal inflection point, offering a rare asymmetric risk/reward setup. Lytenava's European approval, decade-long exclus...
